임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 3상모집 예정· Schizophrenia; Psychosis조현병 성인 환자에서 24주 및 52주 치료 후 크산올리딘/트로스피움(XT)의 인지장애 개선 효능 평가 연구
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
협력: BMS
- 3상모집 예정· Pulmonary Fibrosis폐섬유증 환자에서 애드밀파란트의 안전성 및 내약성을 평가하는 장기 추적 연구
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
리드: BMS
- 1/2상모집 예정· Arthritis, RheumatoidA Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
리드: BMS
- 3상모집 예정· Irritability Associated With Autism Spectrum DisorderA Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
리드: BMS
- 3상모집 예정· Irritability Associated With Autism Spectrum DisorderA Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
리드: BMS
- 2상모집 예정· Chronic Immune ThrombocytopeniaStudy of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
리드: BMS
- 2상모집 예정· Locally Advanced Non-Small Cell Lung Cancer (NSCLC)A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
리드: BMS
- 4상모집 예정· Healthy VolunteersStudy to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers
협력: BMS
- 1/2상모집 중· Antineutrophil Cytoplasmic Antibody-associated VasculitisCC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
협력: BMS
- 1/2상모집 중· SCHIZOPHRENIA 1 (Disorder)A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
협력: BMS
- 1상모집 예정· Large B-cell LymphomaGolcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
협력: BMS
- 2상모집 중· Central Centrifugal Cicatricial AlopeciaDeucravacitinib in the Treatment of Cicatricial Alopecias
협력: BMS
- 2상모집 중· Phase 2 StudyA Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
협력: BMS
- 단계 미표기모집 중· Ulcerative ColitisA Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
리드: BMS
- 1상모집 중· Diffuse Pleural MesotheliomaA Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
협력: BMS
- 1상모집 중· Colorectal CancerA Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
협력: BMS
- 1/2상모집 중· Advanced Renal Cell Carcinoma (RCC)A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
리드: BMS · 협력: 바이오엔테크
- 단계 미표기모집 중· Non Small Cell Lung Cancer NSCLCA Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)
협력: BMS
- 3상모집 중· Non-small Cell Lung Cancer (NSCLC)A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
리드: BMS · 협력: 바이오엔테크
- 1/2상모집 중· Hepatocellular Carcinoma (HCC)A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
리드: BMS · 협력: 바이오엔테크
- 2/3상모집 중· Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
리드: BMS · 협력: 바이오엔테크
- 3상모집 중· Non-Small Cell Lung Cancer (NSCLC)A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
리드: BMS · 협력: 바이오엔테크
- 단계 미표기모집 중· Lung Non-Small Cell CarcinomaExperiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
협력: BMS
- 단계 미표기모집 중· Unresectable Hepatocellular CarcinomaFirst-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)
리드: BMS
- 1상모집 중· Rheumatoid ArthritisA Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis
리드: BMS
- 단계 미표기모집 중· SchizophreniaEffectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
리드: BMS
- 1상모집 중· Healthy VolunteersA Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants
리드: BMS
- 2상모집 중· Cutaneous MelanomaNeo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
협력: BMS
- 1/2상모집 중· Relapsed/Refractory Small Cell Lung CancerA Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
리드: BMS
- 단계 미표기모집 중단 (진행 중)· Lower-risk Myelodysplastic Syndromes (TD LR-MDS)A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain
리드: BMS
- 2상모집 예정· Relapsed or Refractory Multiple Myeloma (RRMM)A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
협력: BMS
- 단계 미표기모집 중· Ulcerative Colitis (UC)Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis
리드: BMS
- 단계 미표기모집 중단 (진행 중)· SchizophreniaReal-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users
리드: BMS
- 1상모집 중· Renal Cell CarcinomaA First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
리드: BMS
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.